New
guidelines from the US Department of Health and Human Services (HHS) recommend
that naloxone should be prescribed or coprescribed with opioids to individuals
at high risk of an overdose, including, but not limited to: individuals who are
on relatively high doses of opioids, take other medications which enhance
opioid complications, or have underlying health conditions.
The
guideline also recommends that doctors should also educate patients and those
who are likely to respond to an overdose, including family members and friends,
on when and how to use naloxone.
The
following patients should be prescribed or coprescribed naloxone:
· Are receiving opioids
at a dosage of 50 morphine milligram equivalents (MME) per day or greater
· Have respiratory
conditions such as chronic obstructive pulmonary disease (COPD) or obstructive
sleep apnea (regardless of opioid dose)
· Have been prescribed
benzodiazepines (regardless of opioid dose).
· Have a non-opioid
substance use disorder, report excessive alcohol use, or have a mental health
disorder (regardless of opioid dose)
Patients
at high risk for experiencing or responding to an opioid overdose have also
been defined. These include individuals:
· Using heroin, illicit
synthetic opioids or misusing prescription opioids
· Using other illicit
drugs such as stimulants, including methamphetamine and cocaine, which could
potentially be contaminated with illicit synthetic opioids like fentanyl
· Receiving treatment
for opioid use disorder, including medication-assisted treatment with
methadone, buprenorphine, or naltrexone
· With a history of
opioid misuse that were recently released from incarceration or other
controlled settings where tolerance to opioids has been lost
(Source:
https://www.hhs.gov/opioids/sites/default/files/2018-12/naloxone-coprescribing-guidance.pdf)
Dr KK
Aggarwal
Padma
Shri Awardee
President
Elect Confederation of Medical Associations in Asia and Oceania (CMAAO)
Group
Editor-in-Chief IJCP Publications
President
Heart Care Foundation of India
Immediate
Past National President IMA
No comments:
Post a Comment